TapImmune Inc. is a leader in the development of novel immunotherapies for cancer, with multiple Phase 2 and Phase 1b/2 clinical studies, Among its major competitors, TapImmune is ranked in 10th place for NPS while Alzheon is 1st, and Merck is 2nd.